CTLA4 and myeloid sarcoma: Interestingly, we found that treatment with Fingolimod significantly increases the expression of both CTLA-4 and PD-L1 in the PBMC of RRMS patients compared to the naïve MS patients (Figure 3B and Figure 4B).